Twist Bioscience reports record Q1 revenue of $71.5M (+32% YoY); raises FY2024 guidance to $288M-$293M

Twist Bioscience Corp

2024-Q1 EPS reported -$0.75 revenue$71,498,000

Orders increased 19% YoY to $77.5M; NGS revenue grew 61% to $39.4M.
Net loss of $43.0M ($0.75 per share) vs. $41.8M ($0.74 per share) in prior year.
Gross margin reached 40.5%, above previous guidance; FY2024 margin guidance raised to 40%-41%.
Appointed Adam Laponis as CFO; expanded Express Genes service to all prep scales.
Cash and investments of $311.1M as of Dec 31, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Twist Bioscience Corp reported the first quarter of fiscal 2024 ended December 31, 2023 results: revenue $71.5 million, net income Net loss attributable to common stockholders for the first quarter of fiscal 2024 was $43.0 million, or $0.75 per share, EPS $0.75 per share. Guidance raised.

Period: the first quarter of fiscal 2024 ended December 31, 2023
Revenue: $71.5 million
Net income: Net loss attributable to common stockholders for the first quarter of fiscal 2024 was $43.0 million, or $0.75 per share
EPS: $0.75 per share
Guidance: raised
Result: reported results

Exact text from the filing

reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023. "We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "In SynBio,

View on SEC.gov

Browse all earnings releases →

Twist Bioscience Corp filing history →

Source: SEC EDGAR

accession 0001628280-24-002998

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.